Please confirm topic selection

Are you sure you want to trigger topic in your Anconeus AI algorithm?

4.1

  • star icon star icon star icon
  • star icon star icon star icon
  • star icon star icon star icon
  • star icon star icon star icon
  • star icon star icon star icon

(55)

Images
https://upload.orthobullets.com/topic/8050/images/Xray lateral_moved.jpg
https://upload.orthobullets.com/topic/8050/images/2b_moved.jpg
https://upload.orthobullets.com/topic/8050/images/q4-1d[1]_moved.jpg
https://upload.orthobullets.com/topic/8050/images/23_moved.JPG
https://upload.orthobullets.com/topic/8050/images/40a_moved.jpg
https://upload.orthobullets.com/topic/8050/images/pvns ankle mri t2.jpg
https://upload.orthobullets.com/topic/8050/images/pvns_sag_knee_illustration..jpg
  • Summary
    • Pigmented Villonodular Synovitis is a locally aggressive neoplastic synovial disease (not a true neoplasm) characterized by joint effusions, expansion of the synovium, and bony erosions.
    • The condition usually presents in patients between 30 and 40 years old with recurrent atraumatic knee hemarthrosis.
    • Diagnosis is multifaceted with clinical assessment for joint effusion (most commonly the knee), MRI studies showing synovial expansion, arthrocentesis revealing a brown fluid, and biopsy revealing hemosiderin-stained multinucleated giant cells.
    • Treatment generally consists of partial or total surgical synovectomy depending on presence of localized or diffuse PVNS. 
  • Epidemiology
    • Incidence
      • rare
        • 9.2 per million per year in the United States
    • Demographics
      • most commonly in adults age 30-40 but can occur at any age
      • equal incidence in men and women
    • Anatomic location
      • may occur locally (within a joint) or diffusely
      • localized (intra-articular or classic form)
        • anterior knee is the most common site of involvement (80%)
          • most commonly affects the patellofemoral compartment at the infrapatellar fat pad
        • knee > hip > ankle > shoulder > elbow
      • diffuse (extra-articular extension)
        • behaves differently from localized
  • Etiology
    • Pathophysiology
      • pathobiology
        • caused by an overexpression of CSF1 gene
          • overexpression leads to clusters of aberrant cells creating focal areas of soft tissue hyperplasia in the synovial cells lining joints
        • a locally aggressive neoplastic synovial disease (not a true neoplasm)
    • Genetics
      • mutations
        • locations of chromosome 1p13 in majority of cases
        • 5q33 chromosomal rearrangement
    • Associated conditions
      • Giant Cell Tumor of Tendon Sheath
        • also known as pigmented villonodular tumor of the tendon sheath (PVNTS)
  • Classification
      • Localized versus Diffuse PVNS
      • Characteristic
      • Localized PVNS
      • Diffuse PVNS
      • Location
      • Knee > hip > ankle
      • Knee (75%)
      • Age
      • 30-50y
      • <40y
      • Gender
      • Male = Female
      • Female =/> Male
      • Presentation
      • Painless, swollen joint, longstanding
      • Painful, swollen, tender, limited mobility
      • Radiograph
      • Osseous erosion from localized pressure
      • Degenerative changes on both sides of the joint
      • MRI
      • Well circumscribed soft tissue mass
      • Ill-defined (poorly circumscribed) soft tissue mass
      • Recurrence
      • 8% after synovectomy
      • 30% after synovectomy
  • Presentation
    • History
      • 50% of patients will have a prior history of trauma to the area
    • Symptoms
      • common symptoms
        • insidious onsent of pain in affected joint
        • stiffness in the affected joint
        • swelling in the affected joint
      • recurrent atraumatic hemarthrosis
        • is hallmark of disorder
    • Physical exam
      • inspection
        • joint effusion
        • erythema
      • palpation
        • tenderness along joint line
      • motion
        • limited motion of affected joint
  • Imaging
    • Radiographs
      • recommended views
        • AP and lateral of affected joint
      • findings
        • soft tissue swelling
        • may show cystic erosion with sclerotic margins on both sides of the joint
    • CT
      • indications
        • to evaluate for extent of cystic bone loss
      • findings
        • may show cystic erosions on both sides of the joint similar to radiographs
    • MRI
      • indications
        • most sensitive imaging study
        • provides excellent delineation of both intra-articular and extra-articular disease
      • findings
        • reveals joint effusion, hemosiderin deposits, expansion of the synovium, and bony erosion
        • low signal intensity on T1
          • due to hemosiderin deposits
          • presence of fat signal (T1) within the lesion
        • low signal intensity on T2
        • "blooming artifact"
          • signal loss on gradient-echo sequences
          • because of iron in hemosiderin
        • extra-articular extension
          • commonly see posterior extension outside of the knee joint of an intra-articular process
  • Studies
    • Labs
      • CRP and ESR
        • often normal despite signs of soft tissue swelling
    • Arthrocentesis
      • indication
        • recurrent hemarthrosis
      • findings
        • grossly bloody effusion
    • Diagnostic arthroscopy
      • indications
        • gold standard for diagnosis
        • synovial biopsy should be performed
      • findings
        • brownish or reddish inflamed synovium is typical of PVNS
        • frond-like pattern of papillary projections
    • Histology
      • gross histology
        • shows a proliferative mass extending from the synovium
      • low power
        • mononuclear stromal cells infiltrating the synovium
        • highly vascular villi lined with plump hyperplastic synovial cells
      • high power
        • hemosiderin stained multinucleated giant cells
        • pigmented foam cells (lipid-laden histiocytes)
        • mitotic figures common
  • Differential
    • Synovial chondromatosis
    • Hemophilia/hemarthrosis
    • Rheumatoid arthritis
    • Septic joints
    • Other neoplasia
  • Treatment
    • Nonoperative
      • observation
        • indications
          • asymptomatic disease only
      • CSF-1 receptor antagonist (pexidartinib)
        • indications
          • approved in 2019 for use in patients with extensive disease who are not likely to benefit from surgical intervention
    • Operative
      • partial synovectomy
        • indications
          • local form of PVNS
        • technique
          • if lesion is accessible from anterior knee, this is can be done arthroscopically
          • posterior or extra-articular lesions should be performed open
      • total synovectomy +/- external beam radiation
        • indications
          • in grossly symptomatic and painful disease
        • technique
          • total synovectomy is classified as marginal excision
          • techniques range from arthroscopic to fully open total synovectomy depending on extent and location of disease
        • outcomes
          • improved functional and range of motion outcomes with arthroscopic technique
          • frequent recurrence is common
            • mostly due to incomplete synovectomy
        • external beam irradiation
          • technique
            • 30-35Gy in 15 fractions, or 50Gy in 25 fractions
          • outcomes
            • when combined with total synovectomy, reduces rate of recurrence to 10-20%
      • total synovectomy and total joint arthroplasty
        • indications
          • advanced disease with severe degenerative joint changes i knee, hip, and shoulder
      • total synovectomy and arthrodesis
        • indications
          • severe disease of the ankle
  • Techniques
    • CSF-1 receptor antagonist (pexidartinib)
      • technique
        • oral medication taken once daily for 24 weeks showed significant improvement of PVNS disease burden in ~40% of patients.
      • complications
        • cholestatic hepatotoxicity was a noted side-effect of the drug
    • Arthroscopic synovectomy of knee for PVNS
      • approach
        • routine arthroscopic portals for knee, ankle, and shoulder
      • technique
        • perform as thorough resection of synovium as possible through portals
        • can be challenging to access the posterior portions of the joint or extra-articular disease
    • Open posterior synovectomy of knee for PVNS
      • approach
        • posterior approach to the knee via transverse or S-shape incision across popliteal fossa
        • approach between medial and lateral heads of gastrocnemius
        • retract neurovascular bundle to access posterior joint capsule
      • technique
        • disease is often seen posterior and extra-articular to the knee
        • complete posterior synovectomy and resection of extra-articular disease
      • complications
        • posterior approach to the knee places popliteal neurovascular bundle at risk
  • Complications
    • Recurrence
      • incidence
        • recurrence is the most frequent complication for both intra-articular and extra-articular disease
          • 30%-50% recurrence rate despite complete synovectomy
            • same rates for complete open vs open+arthroscopic
          • rates can be reduced with addition of external beam radiation
    • Joint destruction
      • moderate to severe joint deformity
      • treatment
        • may lead to the need for arthrodesis or amputation
    • Skin necrosis, radiation induced sarcoma
      • risk factors
        • radiation therapy
  • Prognosis
    • PVNS is associated with a high rate of recurrence and accelerated degenerative changes of the knee ultimately requiring arthroplasty
      • TKA in patients with PVNS is associated with complication rates
Card
1 of 44
Question
1 of 21
SORT BY:
INCLUDE:
Private Note

Attach Treatment Poll
Treatment poll is required to gain more useful feedback from members.
Please enter Question Text
Please enter at least 2 unique options
Please enter at least 2 unique options
Please enter at least 2 unique options